论文部分内容阅读
舒尼替尼是一种口服多靶点受体酪氨酸激酶抑制剂,用于治疗转移性肾细胞癌和伊马替尼治疗失败或不耐受的转移性胃肠道间质瘤。舒尼替尼致甲状腺功能减退的发生率较高,症状不典型,包括乏力、心悸、畏寒、嗜睡等,易与肿瘤相关症状及舒尼替尼的其他常见不良反应混淆。舒尼替尼致甲状腺功能减退可能与破坏甲状腺腺体、抑制甲状腺过氧化物酶和损伤血管有关。服用舒尼替尼的患者需定期监测甲状腺功能,必要时给予甲状腺激素替代治疗。
Sunitinib is an oral multi-target receptor tyrosine kinase inhibitor for the treatment of metastatic renal cell carcinoma and metastatic gastrointestinal stromal tumors of failed or intolerant imatinib treatment. Sunitinib caused a higher incidence of hypothyroidism, atypical symptoms, including fatigue, palpitations, chills, drowsiness, etc., easily confused with tumor-related symptoms and other common side effects of sunitinib. Sunitinib induced hypothyroidism may be related to the destruction of the thyroid gland, inhibition of thyroid peroxidase and vascular injury. Patients taking sunitinib should be regularly monitored thyroid function, if necessary, give thyroid hormone replacement therapy.